PT3045474T - Agentes terapêuticos para o tratamento de doenças associadas à proliferação celular indesejada - Google Patents

Agentes terapêuticos para o tratamento de doenças associadas à proliferação celular indesejada

Info

Publication number
PT3045474T
PT3045474T PT161550090T PT16155009T PT3045474T PT 3045474 T PT3045474 T PT 3045474T PT 161550090 T PT161550090 T PT 161550090T PT 16155009 T PT16155009 T PT 16155009T PT 3045474 T PT3045474 T PT 3045474T
Authority
PT
Portugal
Prior art keywords
treatment
therapeutic agents
cell proliferation
diseases associated
undesired cell
Prior art date
Application number
PT161550090T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Fundacio Privada Inst Dinvestigacio Oncològica De Vall Dhebron
Fundacio Privada Institut De Recerca Hospital Univ Vall Hebron
Fundacio Privada Inst Catalana De Recerca I Estudis Avancats
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Privada Inst Dinvestigacio Oncològica De Vall Dhebron, Fundacio Privada Institut De Recerca Hospital Univ Vall Hebron, Fundacio Privada Inst Catalana De Recerca I Estudis Avancats filed Critical Fundacio Privada Inst Dinvestigacio Oncològica De Vall Dhebron
Publication of PT3045474T publication Critical patent/PT3045474T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
PT161550090T 2009-04-03 2010-04-06 Agentes terapêuticos para o tratamento de doenças associadas à proliferação celular indesejada PT3045474T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200900928A ES2363358B1 (es) 2009-04-03 2009-04-03 Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.

Publications (1)

Publication Number Publication Date
PT3045474T true PT3045474T (pt) 2021-03-22

Family

ID=42342718

Family Applications (1)

Application Number Title Priority Date Filing Date
PT161550090T PT3045474T (pt) 2009-04-03 2010-04-06 Agentes terapêuticos para o tratamento de doenças associadas à proliferação celular indesejada

Country Status (24)

Country Link
US (4) US10100112B2 (cg-RX-API-DMAC7.html)
EP (2) EP2414394A2 (cg-RX-API-DMAC7.html)
JP (5) JP6207836B2 (cg-RX-API-DMAC7.html)
KR (6) KR20190093691A (cg-RX-API-DMAC7.html)
CN (2) CN102574918A (cg-RX-API-DMAC7.html)
AU (1) AU2010233791B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1015369A2 (cg-RX-API-DMAC7.html)
CA (1) CA2757680C (cg-RX-API-DMAC7.html)
CY (1) CY1124148T1 (cg-RX-API-DMAC7.html)
DK (1) DK3045474T3 (cg-RX-API-DMAC7.html)
EA (1) EA201101450A1 (cg-RX-API-DMAC7.html)
ES (2) ES2363358B1 (cg-RX-API-DMAC7.html)
HR (1) HRP20210352T1 (cg-RX-API-DMAC7.html)
HU (1) HUE054196T2 (cg-RX-API-DMAC7.html)
IL (1) IL215467A (cg-RX-API-DMAC7.html)
LT (1) LT3045474T (cg-RX-API-DMAC7.html)
MX (1) MX336903B (cg-RX-API-DMAC7.html)
PL (1) PL3045474T3 (cg-RX-API-DMAC7.html)
PT (1) PT3045474T (cg-RX-API-DMAC7.html)
SG (2) SG175032A1 (cg-RX-API-DMAC7.html)
SI (1) SI3045474T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100153T1 (cg-RX-API-DMAC7.html)
WO (1) WO2010115868A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201107215B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007010394A2 (en) * 2005-07-19 2007-01-25 Stemgen S.P.A. Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps
EP2371860A1 (en) 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
JP2015071566A (ja) * 2013-10-03 2015-04-16 住友ベークライト株式会社 Ｆｇｆ４遺伝子増幅腫瘍の医薬組成物
CA2941703A1 (en) * 2014-03-11 2015-09-17 Godavari Biorefineries Limited Cancer stem cell targeting compounds
CN106659775B (zh) * 2014-06-30 2021-08-06 阿尔托生物科学有限公司 基于il-15的分子及其方法和用途
WO2016040657A1 (en) * 2014-09-10 2016-03-17 The Regents Of The University Of California TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES
EP3067422B1 (en) * 2015-03-13 2024-07-31 Sabanci Üniversitesi Ct-1 inhibitors
CA2981173C (en) 2015-03-23 2024-01-02 Evestra, Inc. Novel cytotoxic agents that preferentially target leukemia inhibitory factor (lif) for the treatment of malignancies and as new contraceptive agents
EP3173483A1 (en) 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
WO2018115960A1 (en) 2016-12-19 2018-06-28 Mosaic Biomedicals, S.L. Antibodies against lif and uses thereof
KR102716931B1 (ko) 2016-12-19 2024-10-15 펀다시오 프리바다 인스티튜시오 카탈라나 드 르세르카 아이 에스투디스 아반카츠 Lif에 대한 항체 및 이의 용도
KR20210008514A (ko) * 2018-05-14 2021-01-22 메디뮨 리미티드 Lif에 대한 항체 및 이의 투여 형태
JP7379390B2 (ja) * 2018-06-18 2023-11-14 メドイミューン・リミテッド 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ
AU2019291305B2 (en) * 2018-06-18 2024-03-21 Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats Methods for improving response to anti-LIF antibody treatment in individuals with cancer
WO2020056349A2 (en) * 2018-09-13 2020-03-19 Evestra, Inc. Lif/lifr antagonist oncology and nonmalignant diseases
CA3135694A1 (en) * 2019-04-17 2020-10-22 Hiroshima University Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
CN111020030A (zh) * 2019-12-03 2020-04-17 中山大学 一种骨肉瘤干细胞标志物及其应用、试剂盒
EP3988116A1 (en) * 2020-10-23 2022-04-27 Consejo Superior De Investigaciones Científicas (CSIC) Methods and compositions for the treatment of hematologic malignancies

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
EP0321201B2 (en) 1987-12-15 2004-11-24 Gene Shears Pty Limited Ribozymes
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
GB9004890D0 (en) * 1990-03-05 1990-05-02 Heath John K Leukaemia inhibitory factor
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
JPH05304986A (ja) * 1992-04-28 1993-11-19 Tosoh Corp ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
WO1993023556A1 (en) 1992-05-08 1993-11-25 Genentech, Inc. Antibodies to leukemia inhibitory factor
GB9413316D0 (en) 1994-07-01 1994-08-24 Cancer Res Campaign Tech Novel proteins
US6251588B1 (en) 1998-02-10 2001-06-26 Agilent Technologies, Inc. Method for evaluating oligonucleotide probe sequences
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
PL220113B1 (pl) 1999-01-15 2015-08-31 Genentech Inc Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc
ES2313883T3 (es) * 1999-02-12 2009-03-16 The Scripps Research Institute Procedimientos para el tratamiento de tumores y metastasis utilizando una combinacion de terapias antiangiogenicas e inmunoterapias.
US6110462A (en) 1999-03-03 2000-08-29 The Scripps Research Institute Enzymatic DNA molecules that contain modified nucleotides
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
EP1497445A2 (en) 2002-04-01 2005-01-19 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
JP2006512924A (ja) * 2002-08-15 2006-04-20 ジェンザイム・コーポレーション 脳内皮細胞発現パターン
US20060078533A1 (en) * 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004067778A2 (en) * 2003-01-28 2004-08-12 University Of South Florida Differentially expressed genes in large granular lymphocyte leukemia
WO2005030803A1 (en) * 2003-09-29 2005-04-07 The Walter And Eliza Hall Institute Of Medical Research Therapeutic molecules
CN101052717A (zh) 2004-05-11 2007-10-10 α基因株式会社 诱发rna干扰的多核苷酸以及使用该多核苷酸的基因表达抑制方法
KR20110068987A (ko) * 2008-08-29 2011-06-22 제넨테크, 인크. Ｖｅｇｆ-비의존적 종양의 진단 및 치료
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
WO2018115960A1 (en) * 2016-12-19 2018-06-28 Mosaic Biomedicals, S.L. Antibodies against lif and uses thereof

Also Published As

Publication number Publication date
EA201101450A1 (ru) 2012-04-30
US20200385455A1 (en) 2020-12-10
AU2010233791A1 (en) 2011-11-03
KR20200078668A (ko) 2020-07-01
US20120114671A1 (en) 2012-05-10
ES2363358B1 (es) 2012-06-21
CN102574918A (zh) 2012-07-11
WO2010115868A3 (en) 2011-02-03
CY1124148T1 (el) 2022-05-27
CN107964043A (zh) 2018-04-27
KR102373754B1 (ko) 2022-03-15
SG10202010568RA (en) 2020-11-27
KR20220035978A (ko) 2022-03-22
JP2019006784A (ja) 2019-01-17
EP3045474A3 (en) 2016-09-28
KR20120100703A (ko) 2012-09-12
HRP20210352T1 (hr) 2021-05-28
JP2016040255A (ja) 2016-03-24
MX336903B (es) 2016-02-04
US20240400667A1 (en) 2024-12-05
ES2864639T3 (es) 2021-10-14
US10100112B2 (en) 2018-10-16
EP3045474B1 (en) 2021-01-13
JP6207836B2 (ja) 2017-10-04
AU2010233791B2 (en) 2016-01-21
EP3045474A2 (en) 2016-07-20
MX2011010425A (es) 2012-03-06
US20190211095A1 (en) 2019-07-11
SMT202100153T1 (it) 2021-05-07
WO2010115868A2 (en) 2010-10-14
IL215467A (en) 2016-06-30
BRPI1015369A2 (pt) 2021-06-29
JP2012522756A (ja) 2012-09-27
SG175032A1 (en) 2011-11-28
LT3045474T (lt) 2021-05-10
KR20180079470A (ko) 2018-07-10
JP7197665B2 (ja) 2022-12-27
SI3045474T1 (sl) 2021-07-30
HUE054196T2 (hu) 2021-08-30
ES2363358A1 (es) 2011-08-01
JP2022031742A (ja) 2022-02-22
DK3045474T3 (da) 2021-03-22
ZA201107215B (en) 2012-12-27
KR20190093691A (ko) 2019-08-09
CA2757680C (en) 2021-11-02
KR20170121319A (ko) 2017-11-01
JP2020090522A (ja) 2020-06-11
CA2757680A1 (en) 2010-10-14
IL215467A0 (en) 2011-12-29
EP2414394A2 (en) 2012-02-08
US11999782B2 (en) 2024-06-04
PL3045474T3 (pl) 2021-08-09

Similar Documents

Publication Publication Date Title
SG10202010568RA (en) Therapeutic Agents For The Treatment Of Diseases Associated With Undesired Cell Proliferation
IL259475A (en) Combined therapy for the treatment of diabetes
IL216399A0 (en) Pharmaceutical composition for the treatment of heart diseases
IL200862A0 (en) 3-imidazolyl-indoles for the treatment of proliferative diseases
IL200368A0 (en) Treatment of diseases characterized by inflammation
PL2643004T3 (pl) Kompozycja oligosacharydów do leczenia chorób skóry
ZA201106730B (en) Methods of treatment using combination therapy
ZA201301601B (en) Treatment of diseases
GB0921075D0 (en) Novel combination of the therapeutic agents
IL218283A0 (en) Combination therapy for treating proliferative diseases
HUE039768T2 (hu) Terápiás szer anaerob betegségekre
ZA200905364B (en) Treatment of diseases characterized by inflammation
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
ZA201300762B (en) Novel combination therapy for the treatment of cancer
GB201202095D0 (en) Topical medicament for the treatment of psoriasis
IL275636A (en) Medical combination for cancer treatment
IL216491A0 (en) Combination therapy for the treatment of multiple myeloma
EP2564849A4 (en) PROPHYLACTIC OR THERAPEUTIC FOR DISEASES RELATED TO PAIN IN THE HARNTRAKT
PL2424529T3 (pl) Nowe postępowania terapeutyczne z zastosowaniem centakwiny
GB0901727D0 (en) The treatment of ophthalmic diseases
GB0801511D0 (en) The treatment of ophthalmic diseases
IL222623A (en) Preparations and kits for medical treatment
GB0700755D0 (en) The Treatment of ophthalmic diseases
GB0915802D0 (en) Therapeutic treatments
GB0805119D0 (en) Treatment of myelination diseases